Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, we also demonstrated that sGC inhibitor treatment repressed tumor growth in TMPRSS2-ERG-positive PCa xenograft models and can act in synergy with a potent AR antagonist, enzalutamide.
|
30718921 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In patients without prior A/E, blood and tumor TMPRSS2-ERG independently predicted lower PSA-PFS (HR 3.3, 95% CI 1.4-7.9 and HR 1.8, 95% CI 1.02-3.3, respectively) to taxanes.
|
30807643 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we report a frequency of 13% for TMPRSS2-ERG in tumors from Black South Africans.
|
31090091 |
2019 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition, loss of S100A8 expression was associated with TMPRSS2:ERG fusions (P < .0001), deletions of PTEN, 3p, and 6q (P < .005), and a high number of genomic deletions per tumor (P = .0009).
|
31382165 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Separate calculations in 3854 cancers with and 4768 cancers without <i>TMPRSS2:ERG fusion</i> revealed that these associations with tumor phenotype and patient outcome were largely driven by the subset of ERG-negative tumors.
|
31296150 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prostate cancer (PCa) tumors harboring translocations of ETS family genes with the androgen responsive TMPRSS2 gene (ETS+ tumors) provide a robust biomarker for detecting PCa in approximately 70% of patients.
|
30367117 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We hypothesize that enzalutamide treatment will be more effective in cells/tumors with TMPRSS2-ERG translocations because these tumors have increased AR signaling.
|
31638934 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Subgroup analyses revealed, that the prognostic value of CEBPA loss was entirely driven by tumors carrying both TMPRSS2:ERG fusions and PTEN deletions.
|
30430607 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor ERG protein expression (a <i>TMPRSS2:ERG</i> marker) was immunohistochemically assessed.
|
29167279 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TMPRSS2-ERG-positive and -negative prostate cancer specimens have distinct intratumoral androgen profiles, possibly due to activation of testosterone-independent DHT biosynthesis via the alternative pathway in TMPRSS2-ERG-positive tumors.
|
29773553 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer progression is driven by genome instability incurred rearrangements such as transmembrane protease, serine 2 (TMPRSS2)/v-ets erythroblastosis virus E26 oncogene (ERG) that could possibly turn some of the tumor suppressor micro-RNAs into pro-oncogenic ones.
|
28050800 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We further conducted a systematic review and meta-analysis of TMPRSS2:ERG fusions in relation to race, Gleason score, and tumor stage, combining results from Ghana with 40 additional studies.
|
28633309 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we analyzed the status of <i>TMPRSS2-ERG</i> fusion genes and interstitial genes in tumors from a large cohort of men treated surgically for prostate cancer, associating alterations with biochemical progression.
|
29127096 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Two studies found that the associations between obesity and prostate cancer (ie, fewer low-grade cancers and yet more aggressive cancers) was limited to men with TMPRSS2-ERG-positive tumors.
|
27771128 |
2017 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The complete absence of ERG-positive tumor areas in 6q15-deleted tumor foci further suggest that the functional consequences of 6q15 deletions may prevent the development of TMPRSS2:ERG fusions.
|
26684029 |
2016 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
First, PTEN deletion without TMPRSS2/ERG rearrangement was enriched in pT3/4 tumors (70% versus 48%) and tumors with Gleason grades of 8 to 9 (60% versus 17%) compared with the entire cohort.
|
26752304 |
2016 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A combination of high preoperative serum PSA and high expression of TMPRSS2-ERG could be promising in distinguishing those tumors that are aggressive and life-threatening.
|
27630329 |
2016 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
FISH for AR-amplification and TMPRSS2-ERG translocation were successful in 54% and 32% in metastatic biopsies and primary tumors, respectively.
|
27391263 |
2016 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Collectively, our findings established that Ets2 is a tumor suppressor gene in prostate cancer, and its loss along with other genes within the TMPRSS2-ERG interstitial region contributes to disease progression.
|
26880803 |
2016 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TRIM25 binds full-length ERG, and it also binds the N-terminally truncated variants of ERG that are expressed in tumors with TMPRSS2-ERG fusions.
|
27626314 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The TMPRSS2-ERG gene rearrangement status of patient samples was determined by transformation of the exon array and RNA seq expression data to robust z-scores followed by the application of a threshold>3 to define a positive TMPRSS2-ERG gene fusion event in a tumour sample.
|
26575822 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lastly, we found that the ability of TMPRSS2 to promote prostate cancer tumor growth and metastasis was associated with increased matriptase activation and enhanced degradation of extracellular matrix nidogen-1 and laminin β1 in tumor xenografts.
|
26018085 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.
|
25852077 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An improved understanding of the genetic basis of prostate carcinogenesis has produced an increasing number of potential prognostic and predictive tools, such as transmembrane protease, serine2:v-ets avian erythroblastosis virus E26 oncogene homolog (TMPRSS2:ERG) gene fusion status, loss of the phosphatase and tensin homolog (PTEN) gene, and gene expression signatures utilizing messenger RNA from tumor tissue.
|
25913390 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, decreased PTEN expression, alone (P = 0.041) and also combined with TMPRSS2-ERG (P = 0.04) or with ERG overexpression (P = 0.04) was associated with GS ≥7 tumors.
|
25939480 |
2015 |